MedTrace Logo

Colistin Pharmacokinetics in Continuous Renal Replacement Therapy

NCT02081560 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-03-07

No results posted yet for this study

Summary

The blood concentration of the antibiotic colistin is determined in patients in whom kidney function is reduced such that a renal replacement therapy is needed.

Hypothesis:no dose reduction is needed in patients undergoing continuous renal replacement therapy over 24h because colistin is sufficiently removed by this procedure.

Conditions

Interventions

DRUG

Colistin

Colistin i.v. three times daily as long a necessary for infection treatment

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Natascia Corti, MD · University Hospital Zurich, Dept. of Pharmacology and Toxicology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2015-07-31
Completion
2015-08-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02081560 on ClinicalTrials.gov